| Amer Kadri, | |
|
9500 Euclid Ave, Cleveland, OH 44195-3111 | |
| (216) 444-2273 | |
| Not Available |
| Full Name | Amer Kadri |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285076828 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 35.127747 (Ohio) | Secondary |
| 207R00000X | Internal Medicine | 35.127747 (Ohio) | Primary |
| Entity Name | Hospitalist Medicine Physicians Of Richland County, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639119027 PECOS PAC ID: 4284538430 Enrollment ID: O20031120000557 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
| Entity Name | Hospitalist Medicine Physicians Of Ohio, Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043572290 PECOS PAC ID: 3779749197 Enrollment ID: O20120730000162 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
| Entity Name | Hospitalist Medicine Physicians Of Ohio-tcg, Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750860235 PECOS PAC ID: 3072864099 Enrollment ID: O20181001001695 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
| Entity Name | Hospitalist Medicine Physicians Of Ohio - Akron, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780229419 PECOS PAC ID: 0042647638 Enrollment ID: O20200220000606 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amer Kadri, 9500 Euclid Ave, Cleveland, OH 44195-4008 Ph: () - | Amer Kadri, 9500 Euclid Ave, Cleveland, OH 44195-3111 Ph: (216) 444-2273 |
News Archive
Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mouse model of Friedreich's ataxia (FA) measurably halted cellular damage caused by the degenerative disease.
The report Bowel Cancer: One of Australia's Most Common Diseases, being released this week by the GI CANCER Institute, says that while bowel cancer is one of the most curable diseases when diagnosed at an early stage, over 4,000 Australians continue to die of it each year.
MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
Researchers from North Carolina State University are proposing a health-based approach to identifying groups at high risk of genocide, in a first-of-its-kind attempt to target international efforts to stop these mass killings before they start.
› Verified 6 days ago
Amir Razavi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |